A5055227647- Monoclonal and Polyclonal Antibodies Research
- HER2/EGFR in Cancer Research
- Lymphoma Diagnosis and Treatment
- Endometriosis Research and Treatment
- CAR-T cell therapy research
- Cancer-related gene regulation
- Estrogen and related hormone effects
- Click Chemistry and Applications
- Nuclear Receptors and Signaling
- Peptidase Inhibition and Analysis
- Synthesis and Biological Evaluation
- Adenosine and Purinergic Signaling
- Pharmacological Receptor Mechanisms and Effects
- Immunotherapy and Immune Responses
- Radiopharmaceutical Chemistry and Applications
- Cell Adhesion Molecules Research
- Reproductive System and Pregnancy
- Ovarian cancer diagnosis and treatment
- Cancer Immunotherapy and Biomarkers
- Neuropeptides and Animal Physiology
- Multiple Myeloma Research and Treatments
- Macrophage Migration Inhibitory Factor
Sutro Biopharma (United States)
2016-2019
Pfizer (United States)
2013-2016
The systemic stability of the antibody-drug linker is crucial for delivery an intact conjugate (ADC) to target-expressing tumors. Linkers stable in circulation but readily processed target cell are necessary both safety and potency delivered conjugate. Here, we report a range stabilities auristatin-based payload site-specifically attached through cleavable valine-citrulline-p-aminobenzylcarbamate (VC-PABC) across various sites on antibody. We demonstrate that conjugation site plays important...
STRO-002 is a novel homogeneous folate receptor alpha (FolRα) targeting antibody-drug conjugate (ADC) currently being investigated in the clinic as treatment for ovarian and endometrial cancers. Here, we describe discovery, optimization, antitumor properties of STRO-002. was generated by conjugation cleavable 3-aminophenyl hemiasterlin linker-warhead (SC239) to nonnatural amino acid para-azidomethyl-L-phenylalanine incorporated at specific positions within high affinity anti-FolRα antibody...
// Cristina L. Abrahams 1 , Xiaofan Li Millicent Embry Abigail Yu Stellanie Krimm Sarah Krueger 2 Nancy Y. Greenland 3 Kwun Wah Wen Chris Jones Venita DeAlmeida Willy A. Solis Shannon Matheny Toni Kline Alice Yam Ryan Stafford Arun P. Wiita Trevor Hallam Mark Lupher and Arturo Molina Sutro Biopharma, Inc., South San Francisco, California, USA MI Bioresearch, Ann Arbor, MI, Department of Pathology Laboratory Medicine, University CA, Correspondence to: Molina, email: amolina@sutrobio.com...
Abstract Folate receptor alpha (FolRα) is a glycosylphosphatidylinositol linked cell-surface glycoprotein that widely expressed in serous and epithelial ovarian cancer, endometrial adenocarcinoma, non-small cell lung cancer triple negative breast cancer. In contrast, FolRα expression highly restricted on normal tissues, making it promising target for therapy using antibody drug conjugates (ADCs). We have designed novel, FolRα-targeting ADC, STRO-002, with potent cytotoxic activity expressing...
Abstract OBJECTIVES: Folate receptor alpha (FolRα) is a cell-surface glycoprotein, highly expressed in ovarian and endometrial adenocarcinoma, thus promising target for cancer therapy using antibody drug conjugates (ADCs). Most ADCs currently development are generated by random attachment of the cytotoxic payload to result heterogeneous mixture, comprised many different forms that likely vary stability activity, therefore may be suboptimal therapeutic agents. We have employed an E. coli...
<p>supplementary text and figures</p>
<div>Abstract<p>STRO-002 is a novel homogeneous folate receptor alpha (FolRα) targeting antibody–drug conjugate (ADC) currently being investigated in the clinic as treatment for ovarian and endometrial cancers. Here, we describe discovery, optimization, antitumor properties of STRO-002. STRO-002 was generated by conjugation cleavable 3-aminophenyl hemiasterlin linker-warhead (SC239) to nonnatural amino acid <i>para</i>-azidomethyl-L-phenylalanine incorporated at...
<p>supplementary text and figures</p>
<div>Abstract<p>STRO-002 is a novel homogeneous folate receptor alpha (FolRα) targeting antibody–drug conjugate (ADC) currently being investigated in the clinic as treatment for ovarian and endometrial cancers. Here, we describe discovery, optimization, antitumor properties of STRO-002. STRO-002 was generated by conjugation cleavable 3-aminophenyl hemiasterlin linker-warhead (SC239) to nonnatural amino acid <i>para</i>-azidomethyl-L-phenylalanine incorporated at...